Blog

Molecular profiling of sqNSCLC reveals high incidence of actionable genomic alterations among patients with no history of smoking

Stephen V Liu/X

Jan 22, 2025, 10:25

Molecular profiling of sqNSCLC reveals high incidence of actionable genomic alterations among patients with no history of smoking

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X:

“Comprehensive profiling of sqNSCLC

AGAs were detected in 22.2% of never-smokers

Never-smokers with sqNSCLC had a significantly higher prevalence of actionable MET (9.5% vs 0.4%) and EGFR mutations (7.9% vs 0.4%) compared to ever-smokers.”

Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking

Authors: Joshua E. Reuss, Jacob Zaemes, Nishant Gandhi, Phillip Walker, Sandip P. Patel, Joanne Xiu, Charu Aggarwal, Ari Vanderwalde, Suresh S. Ramalingam, Balazs Halmos, Stephen V. Liu

Molecular profiling of sqNSCLC reveals high incidence of actionable genomic alterations among patients with no history of smoking

Ari Vanderwalde Balazs Halmos cancer Charu Aggarwal Jacob Zaemes Joanne Xiu Joshua E. Reuss Nishant Gandhi OncoDaily Oncology Phillip Walker Sandip P Patel Stephen V Liu Suresh S. Ramalingam Yakup Ergün

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers